An up-to-date review of emerging biologic therapies for hypercholesterolemia

Hypercholesterolemia and other lipid disorders are major causes of atherosclerotic cardiovascular disease (ASCVD). Statins have been the mainstay of lipid-lowering therapy for many years, but they may not be adequate to achieve the target low density lipoprotein (LDL) cholesterol levels and there are other residual lipid risk factors.